학술논문
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Document Type
Article
Author
Ramgopal, Moti N; Castagna, Antonella; Cazanave, Charles; Diaz-Brito, Vicens; Dretler, Robin; Oka, Shinichi; Osiyemi, Olayemi; Walmsley, Sharon; Sims, James; Di Perri, Giovanni; Sutton, Kenneth; Sutherland-Phillips, Denise; Berni, Alessandro; Latham, Christine L; Zhang, Feifan; D'Amico, Ronald; Pascual Bernáldez, Miguel; Van Solingen-Ristea, Rodica; Van Eygen, Veerle; Patel, Parul; Chounta, Vasiliki; Spreen, William R; Garges, Harmony P; Smith, Kimberly; van Wyk, Jean
Source
In The Lancet HIV September 2023 10(9):e566-e577
Subject
Language
ISSN
2352-3018